Goldman Sachs Group, Inc. (The) reiterated their neutral rating on shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) in a research note released on Friday, October 6th, MarketBeat.com reports. The firm currently has a $44.00 price objective on the biopharmaceutical company’s stock.
A number of other equities analysts have also recently commented on JUNO. Morgan Stanley reaffirmed an equal weight rating and issued a $43.00 target price (up from $27.00) on shares of Juno Therapeutics in a report on Friday, October 6th. ValuEngine raised shares of Juno Therapeutics from a sell rating to a hold rating in a report on Tuesday, August 29th. Wells Fargo & Company reaffirmed an outperform rating and issued a $54.00 target price (up from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. Barclays PLC initiated coverage on shares of Juno Therapeutics in a research report on Wednesday, September 6th. They issued an overweight rating and a $55.00 price objective on the stock. Finally, Standpoint Research reiterated a reduce rating on shares of Juno Therapeutics in a research report on Thursday, August 31st. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $37.83.
Juno Therapeutics (NASDAQ JUNO) opened at 43.04 on Friday. Juno Therapeutics has a 52 week low of $17.52 and a 52 week high of $47.03. The company’s market capitalization is $4.51 billion. The stock’s 50 day moving average is $43.16 and its 200 day moving average is $30.34.
Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.24). Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The company had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. During the same period in the previous year, the business posted ($0.64) EPS. The firm’s revenue for the quarter was down 22.8% compared to the same quarter last year. On average, equities research analysts expect that Juno Therapeutics will post ($3.08) earnings per share for the current year.
WARNING: This article was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://baseballnewssource.com/markets/goldman-sachs-group-inc-the-reaffirms-neutral-rating-for-juno-therapeutics-inc-juno/1701509.html.
In related news, General Counsel Bernard J. Cassidy sold 28,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $44.92, for a total value of $1,257,760.00. Following the transaction, the general counsel now directly owns 55,970 shares of the company’s stock, valued at approximately $2,514,172.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Sunil Agarwal sold 7,285 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $44.76, for a total value of $326,076.60. The disclosure for this sale can be found here. Insiders have sold a total of 85,004 shares of company stock valued at $3,551,561 over the last ninety days. Company insiders own 15.26% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Juno Therapeutics by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock valued at $187,879,000 after buying an additional 131,864 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Juno Therapeutics by 2.6% during the 2nd quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock worth $128,357,000 after purchasing an additional 110,503 shares in the last quarter. State Street Corp grew its holdings in shares of Juno Therapeutics by 7.4% during the 2nd quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock worth $96,742,000 after purchasing an additional 222,754 shares in the last quarter. Capital World Investors grew its holdings in shares of Juno Therapeutics by 13.8% during the 2nd quarter. Capital World Investors now owns 2,425,000 shares of the biopharmaceutical company’s stock worth $72,483,000 after purchasing an additional 295,000 shares in the last quarter. Finally, Redmile Group LLC acquired a new stake in shares of Juno Therapeutics during the 2nd quarter worth approximately $66,344,000. 67.38% of the stock is currently owned by hedge funds and other institutional investors.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with our FREE daily email newsletter.